



human breast carcinoma cells (MCF-7), comprising:  
administering to a subject in need thereof, a pharmaceutically effective amount of a compound  
of formula I



wherein:

- (i) R<sub>1</sub> represents an unsubstituted C<sub>6</sub> or C<sub>10</sub> aryl group; or a C<sub>6</sub> aryl group substituted with Me or OMe;
- (ii) A represents O, S; or a sulfur atom oxidized to sulfoxide;
- (iii) the cyclic group labeled F represents an unsubstituted C<sub>6</sub> or C<sub>10</sub> aryl or a C<sub>5</sub> heteroaryl group having nitrogen as a heteroatom or a phenyl group substituted with ethoxycarbonyl function; and
- (iv) Y represents the group



wherein R<sub>2</sub> and R<sub>3</sub> are independently hydrogen; or methyl or ethyl;  
or Y represents the group CH<sub>3</sub>; or (CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub> or an unsubstituted C<sub>5</sub> heteroaryl group  
having nitrogen as a heteroatom; and  
assessing the affects of the administration.

46. The method of claim 45 wherein the chronic myeloid lymphoma cells are  
selected from the group consisting of LAMA, KYO.1 and K562 cell lines.

47. The method of claim 45 wherein the subject is a human or animal.

---